Biosight was founded by Manus J. Donahue, MBA, PhD with the goal of improving the impact of clinical trials, and most importantly the lives of patients, by utilizing both the expertise of healthcare providers and quantitative scientists to take full advantage of the spectrum of theranostic care available today.

​

Manus was educated at Duke University (Physics: BS; Philosophy: BA), The Johns Hopkins University School of Medicine (Biophysics: PhD), and the University of Oxford (Clinical Neurology: fellowship).

​

He is currently a tenured Professor of Neurology in Nashville, TN, with additional experience in industry and federal clinical trial design and review. He has published more than 160 peer-reviewed manuscripts, has research and development or consulting contracts with pharmaceutical and healthcare technology industry partners, has supported more than 20 foundation or government-funded studies as a funded co-investigator or consultant, and serves as an ad hoc member on multiple National Institutes of Health study sections.  

 

Biosight services comprise clinical trial design, imaging technology implementation, data analysis, statistical trial design, and funding application preparation.

​

Since 2019, Biosight has provided consulting and clinical trial design and implementation services primarily for Phase 1 and 2 international clinical trials, with cumulative budgets over $10M.